France is preparing for a significant update to its colorectal cancer screening program. As of March 15, 2026, a novel contract for colorectal cancer screening kits will be implemented, impacting healthcare professionals and patients alike. This transition aims to improve early detection rates of this common and often deadly cancer, but requires careful attention to kit availability and analysis timelines. The new system will streamline the process of obtaining and analyzing these vital tests, offering greater accessibility for those eligible for screening.
Colorectal cancer remains a major public health concern. According to the French National Cancer Institute (INCa), We see the third most frequently diagnosed cancer in France, after breast and prostate cancer. In 2020, there were over 43,000 new cases diagnosed in France. While often treatable when detected early, it is the second leading cause of cancer-related deaths, responsible for over 17,000 deaths in 2018. The organized screening program plays a crucial role in reducing mortality rates by identifying the disease at its most treatable stages.
The change centers around a new market for screening kits, managed by the French Health Insurance (Assurance Maladie). The National Health Insurance Fund (Cnam) oversees the procurement of these kits and the analysis of the immunological tests. This new contract ensures a consistent supply of high-quality kits and standardized analysis procedures across the country. The transition will affect how physicians and pharmacists order and distribute these kits, as well as how patients access and utilize them.
Impact on Healthcare Professionals: Ordering and Stock Management
For physicians and pharmacists, the key change involves the ordering process through AmeliPro, the French Health Insurance professional portal. Any kits ordered on or after March 15, 2026, will be from the new contract. Kits ordered *before* that date, stemming from the previous contract, will still be available for distribution, but have a limited analysis window. Specifically, kits from the old contract can be analyzed by laboratories for up to six months – until September 15, 2026. Healthcare providers are advised to encourage patients with older kits to complete and return them promptly. To avoid waste, it is recommended that doctors and pharmacists avoid building up large stocks of the older kits.
The provider selected to continue managing the program is Cerba Laboratories, responsible for analyzing the samples. They operate with a co-contractor to supply the kits themselves. This continuity of providers aims to ensure a smooth transition and maintain the quality of the screening process. The Assurance Maladie emphasizes the importance of professional engagement in promoting the program and overcoming barriers to participation.
Accessing Colorectal Cancer Screening Kits: Four Convenient Options
France offers multiple avenues for individuals to obtain a colorectal cancer screening kit. Beyond the traditional route of obtaining a kit from a physician, patients can now access them through pharmacists, nurses, and online. Pharmacists must complete specific training through regional cancer screening coordination centers (CRCDC) to be authorized to distribute the kits. Registered nurses are also now authorized to provide these kits, expanding access points for the public. Finally, individuals can order a kit online through the official website, monkit.depistage-colorectal.fr, using FranceConnect for secure authentication.
Understanding the Organized Screening Program and Eligibility
The organized colorectal cancer screening program is available to men and women aged 50 to 74. The screening test itself is an immunological test designed to detect the presence of blood in the stool, a potential indicator of colorectal cancer or precancerous polyps. Every two years, the Assurance Maladie sends an invitation to eligible individuals to obtain a test. Importantly, the analysis of this test is fully covered by the French healthcare system, making it accessible to all eligible citizens.
The Assurance Maladie emphasizes that early diagnosis is key to successful treatment. Nine out of ten cases of colorectal cancer are curable when diagnosed early. The “Mars Bleu” campaign, currently underway in 2026, aims to raise awareness about the importance of screening and encourage participation in the program. This annual campaign highlights the benefits of early detection and provides information about how to access screening resources.
Key Takeaways
- New Kits Available March 15, 2026: A new contract for colorectal cancer screening kits takes effect, ensuring a consistent supply and standardized analysis.
- Old Kits Have Limited Validity: Kits ordered before March 15, 2026, can be analyzed until September 15, 2026.
- Multiple Access Points: Kits are available through physicians, pharmacists (with training), nurses, and online via FranceConnect.
- Screening for Ages 50-74: The program targets men and women aged 50 to 74, with fully covered test analysis.
The implementation of this new contract represents a proactive step towards improving colorectal cancer screening rates in France. By streamlining the process and expanding access, the Assurance Maladie hopes to increase early detection and ultimately reduce the burden of this disease on the French population. The next key date to watch is September 15, 2026, when the analysis of older kits will cease, reinforcing the require for timely testing.
Do you have questions about the new colorectal cancer screening program? Share your thoughts and experiences in the comments below, and please share this article with anyone who might benefit from this information.